MarketCapExport financials
AIM ImmunoTech (AIM)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
AIM ImmunoTech Cash Flow 2025-2008 | AIM
Brief cash flow overview of AIM ImmunoTech
The review uses the five latest available annual reports between 2021 and 2025.
Operating cash flow is negative at -$11 million, leaving internal funding capacity weak.
Positive operating cash flow appeared only 0 times out of five; a stable cash profile has not formed.
Cash flow takeaway
Taken together, AIM ImmunoTech's cash flow indicators point to increased dependence on reserves or outside financing.
Annual Cash Flow AIM ImmunoTech
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow |
-11 M | -14.9 M | -21.3 M | -16.1 M | -14 M | -10.4 M | -9.07 M | -10.6 M | -7.94 M | -7.38 M | -16.1 M | -14 M | -16.8 M | -13.1 M | -10.1 M | -11.9 M | -9.3 M | - |
Depreciation & Amortization |
37 K | 37 K | 39 K | 38 K | 659 K | 665 K | 735 K | 856 K | 948 K | 1.12 M | 941 K | 665 K | 671 K | 643 K | 465 K | 407 K | 359 K | - |
Accounts Payables |
1.63 M | 6.38 M | 6.44 M | 377 K | 198 K | 383 K | 472 K | 680 K | 741 K | 887 K | 1.21 M | 2.08 M | 1.27 M | 2.16 M | 1.68 M | 1.33 M | - | - |
Accounts Receivables |
7 K | - | 1.18 M | 1.68 M | - | 34 K | 44 K | 235 K | 24 K | - | - | - | - | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Cash Flow AIM ImmunoTech
| 2026-Q2 | 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow |
-7.31 M | -2.72 M | - | - | -2.36 M | - | - | - | -4.82 M | - | - | - | -3.68 M | - | -10 M | -5.07 M | -2.76 M | - | -8.22 M | -4.76 M | -3.04 M | - | -7.51 M | -4.52 M | -3.25 M | - | -6.78 M | -4.23 M | -1.46 M | - | -8.22 M | -5.24 M | -2.54 M | - | -7.18 M | -5.3 M | -2.99 M | - | -5.28 M | -2.29 M | -1.04 M | - | - | - | -4.26 M | - | -9.93 M | -6.21 M | -2.9 M | - | -13.6 M | -9.63 M | -5.85 M | - | -8.18 M | -5.48 M | -1.66 M | - | -7.07 M | -4.8 M | -1.82 M |
Depreciation & Amortization |
571 K | 9 K | - | - | 10 K | - | - | - | 9 K | - | - | - | 11 K | - | 29 K | 20 K | 10 K | - | 484 K | 325 K | 162 K | - | 500 K | 340 K | 173 K | - | 557 K | 380 K | 194 K | - | 658 K | 444 K | 216 K | - | 739 K | 504 K | 261 K | - | 854 K | 576 K | 300 K | - | 663 K | 458 K | 180 K | - | 500 K | 332 K | 167 K | - | 504 K | 350 K | 179 K | - | 469 K | 296 K | 149 K | - | 322 K | 198 K | 112 K |
Accounts Payables |
480 K | 1.22 M | 1.25 M | 7.3 M | 6.94 M | 6.38 M | 6.26 M | 5.46 M | 6.57 M | 6.44 M | 2.79 M | 2.15 M | - | 377 K | 957 K | 712 K | 378 K | 198 K | 369 K | 451 K | 189 K | 383 K | 383 K | 383 K | 383 K | 472 K | 472 K | 472 K | 472 K | 680 K | 680 K | 680 K | 680 K | 741 K | 741 K | 741 K | 741 K | 887 K | 887 K | 887 K | 887 K | 1.21 M | 1.21 M | 1.21 M | 1.21 M | 2.08 M | 2.08 M | 2.08 M | 2.08 M | 1.27 M | 1.27 M | 1.27 M | 1.27 M | 2.16 M | 2.16 M | 2.16 M | 2.16 M | 1.68 M | 1.68 M | 1.68 M | 1.68 M |
Accounts Receivables |
7 K | 7 K | - | - | - | - | - | - | - | 1.18 M | 48 K | 33 K | - | 1.68 M | - | - | - | - | 28 K | 28 K | 34 K | 34 K | 34 K | 34 K | 34 K | 44 K | 44 K | 44 K | 44 K | 235 K | 235 K | 235 K | 235 K | 24 K | 24 K | 24 K | 24 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Cash Flow Statement is one of the three key financial reports of the company AIM ImmunoTech, reflecting the actual cash inflows and outflows over a certain period. Unlike the income statement, which shows revenues and expenses on an accrual basis, the cash flow statement focuses on real cash flows — how much cash actually came into the company and how much was spent.
Main Sections of the Cash Flow Statement- Operating Activities
This section reflects cash flows related to the company’s core operations: receipts from sales of goods and services, payments to suppliers, employee salaries, taxes, and other operating expenses. Positive cash flow from operating activities indicates the viability of the business and its ability to generate cash. - Investing Activities
Shows cash movements related to the purchase and sale of long-term assets such as real estate, equipment, and investments in other companies. Negative cash flow here often indicates investments in growth, which can be a positive sign. - Financing Activities
Reflects the inflow and outflow of cash related to raising and repaying capital: issuing shares, loans, dividend payments, and loan repayments. This section shows how the company finances its activities and distributes profits.
The cash flow statement is important for investors because it allows them to assess the company’s real liquidity, showing whether it has enough cash to cover current obligations and investments — this is critical for financial stability. Additionally, it helps analyze the quality of earnings, since profits reported in the income statement can be "paper" profits and may not reflect actual cash inflows; the cash flow statement reveals this difference. The presence of free cash is also crucial for evaluating the company’s ability to finance growth and pay dividends, which is important for investors. Attention should also be paid to prolonged negative cash flows from operating activities, as this may serve as a warning sign of potential problems with the core business.
Cash flow statements of other stocks in the Biotechnology sector
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
Akebia Therapeutics
AKBA
|
$ 0.66 | 15.7 % | $ 170 M |  USA |
 |
Aldeyra Therapeutics
ALDX
|
$ 0.65 | 0.75 % | $ 39 M | USA |
 |
Alnylam Pharmaceuticals
ALNY
|
$ 227.75 | 1.66 % | $ 29.8 B | USA |
 |
iBio
IBIO
|
$ 0.7 | -1.87 % | $ 72.8 M | USA |
 |
ImmuCell Corporation
ICCC
|
$ 10.21 | -0.37 % | $ 92.2 M | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
$ 25.34 | 0.8 % | $ 1.18 B | USA |
 |
Anika Therapeutics
ANIK
|
$ 21.3 | -0.56 % | $ 305 M | USA |
 |
InMed Pharmaceuticals
INM
|
$ 1.57 | 8.68 % | $ 6.54 M |  Canada |
 |
INmune Bio
INMB
|
$ 1.45 | -0.68 % | $ 35.9 M | USA |
 |
Inovio Pharmaceuticals
INO
|
$ 0.88 | -2.31 % | $ 41.3 M | USA |
 |
Insmed Incorporated
INSM
|
$ 93.4 | 0.01 % | $ 18.6 B | USA |
 |
Innoviva
INVA
|
$ 20.92 | 1.23 % | $ 1.41 B | USA |
 |
Iovance Biotherapeutics
IOVA
|
$ 13.76 | -2.38 % | $ 4.92 M | USA |
 |
Innate Pharma S.A.
IPHA
|
$ 1.54 | 2.67 % | $ 138 M |  France |
 |
Johnson & Johnson
JNJ
|
$ 265.65 | 0.68 % | $ 640 B | USA |
 |
BioCryst Pharmaceuticals
BCRX
|
$ 7.88 | 2.94 % | $ 1.65 B | USA |
 |
Kamada Ltd.
KMDA
|
$ 7.88 | 1.42 % | $ 454 M |  Israel |
 |
Black Diamond Therapeutics
BDTX
|
$ 1.69 | -10.37 % | $ 96.1 M | USA |
 |
Krystal Biotech
KRYS
|
$ 312.12 | 0.2 % | $ 9.03 B | USA |
 |
Kura Oncology
KURA
|
$ 9.64 | 0.31 % | $ 845 M | USA |
 |
Kymera Therapeutics
KYMR
|
$ 114.54 | 3.41 % | $ 9.68 B | USA |
 |
Lineage Cell Therapeutics
LCTX
|
$ 0.98 | -2.1 % | $ 226 M | USA |
 |
Ligand Pharmaceuticals Incorporated
LGND
|
$ 304.8 | 0.42 % | $ 5.89 B | USA |
 |
Longeveron
LGVN
|
$ 1.65 | 3.12 % | $ 29 B | USA |
 |
Eli Lilly and Company
LLY
|
$ 1 281.07 | 0.51 % | $ 1.15 T | USA |
 |
Liquidia Corporation
LQDA
|
$ 44.26 | 3.78 % | $ 3.81 B | USA |
 |
Larimar Therapeutics
LRMR
|
$ 2.22 | -5.53 % | $ 184 M | USA |
 |
Lexicon Pharmaceuticals
LXRX
|
$ 1.44 | 1.06 % | $ 523 M | USA |
 |
Moleculin Biotech
MBRX
|
$ 6.85 | 5.38 % | $ 8.11 M | USA |
 |
Madrigal Pharmaceuticals
MDGL
|
$ 442.0 | 1.79 % | $ 9.92 B | USA |
 |
Compugen Ltd.
CGEN
|
$ 1.89 | -2.58 % | $ 177 M | Israel |
 |
MacroGenics
MGNX
|
$ 2.13 | -5.56 % | $ 135 M | USA |
 |
Mirum Pharmaceuticals
MIRM
|
$ 82.03 | 2.04 % | $ 4.12 B | USA |
 |
MannKind Corporation
MNKD
|
$ 3.18 | -0.47 % | $ 972 M | USA |
 |
CNS Pharmaceuticals
CNSP
|
$ 4.53 | -8.85 % | $ 2.01 M | USA |
 |
Curis
CRIS
|
$ 0.37 | -4.25 % | $ 4.87 M | USA |
 |
Moderna
MRNA
|
$ 196.26 | -1.92 % | $ 76.3 B | USA |
 |
Corvus Pharmaceuticals
CRVS
|
$ 10.55 | 0.14 % | $ 833 M | USA |
 |
Maravai LifeSciences Holdings
MRVI
|
$ 7.58 | 3.48 % | $ 1.09 B | USA |
 |
Neurocrine Biosciences
NBIX
|
$ 144.09 | 0.97 % | $ 14.3 B | USA |
 |
Daré Bioscience
DARE
|
$ 0.65 | 0.81 % | $ 7.27 M | USA |
 |
Minerva Neurosciences
NERV
|
$ 2.22 | -3.42 % | $ 18.8 M | USA |
 |
Nektar Therapeutics
NKTR
|
$ 37.37 | 0.39 % | $ 630 M | USA |
 |
Nkarta
NKTX
|
$ 1.81 | 0.84 % | $ 134 M | USA |
 |
NanoViricides
NNVC
|
$ 1.36 | -3.55 % | $ 27.5 M | USA |
 |
Editas Medicine
EDIT
|
$ 2.38 | -0.63 % | $ 211 M | USA |
 |
Nurix Therapeutics
NRIX
|
$ 25.49 | 0.59 % | $ 2.21 B | USA |
 |
Intellia Therapeutics
NTLA
|
$ 11.18 | -0.27 % | $ 1.21 B | USA |